Cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for patients with Waldenström macroglobulinemia in China.
| Publicado en: | Expert Review of Pharmacoeconomics & Outcomes Research pp. 1 - 12 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
Taylor & Francis Ltd
Aug2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Descripción no disponible. |